{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Skin&page=10",
    "query": {
      "condition": "Melanoma, Skin",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 2054,
    "total_pages": 206,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Skin&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Skin&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T03:21:18.900Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00539591",
      "title": "Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "Peginterferon alfa-2b",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Recombinant interferon alfa-2b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 29,
      "start_date": "2008-05-09",
      "completion_date": "2031-05",
      "has_results": true,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-11-19T03:21:18.900Z",
      "location_count": 3,
      "location_summary": "San Diego, California • Memphis, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00539591"
    },
    {
      "nct_id": "NCT04835805",
      "title": "A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Belvarafenib",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2021-05-13",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-11-19T03:21:18.900Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Aurora, Colorado • Iowa City, Iowa + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04835805"
    },
    {
      "nct_id": "NCT03347123",
      "title": "A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Lirilumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2018-03-21",
      "completion_date": "2021-01-29",
      "has_results": true,
      "last_update_posted_date": "2022-02-28",
      "last_synced_at": "2026-11-19T03:21:18.900Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03347123"
    },
    {
      "nct_id": "NCT00002786",
      "title": "Biological Therapy in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic tumor infiltrating lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "1995-10",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2010-05-10",
      "last_synced_at": "2026-11-19T03:21:18.900Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002786"
    },
    {
      "nct_id": "NCT00724841",
      "title": "A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Obatoclax Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gemin X",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2008-06",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2016-07-22",
      "last_synced_at": "2026-11-19T03:21:18.900Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00724841"
    },
    {
      "nct_id": "NCT04093323",
      "title": "Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HLA-A2 Positive Cells Present",
        "Refractory Melanoma"
      ],
      "interventions": [
        {
          "name": "Alpha-type-1 Polarized Dendritic Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "PD-1 Ligand Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "PD1 Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Interferon Alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rintatolimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2024-11-13",
      "completion_date": "2025-06-19",
      "has_results": true,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-11-19T03:21:18.900Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04093323"
    },
    {
      "nct_id": "NCT02775461",
      "title": "Pancreas Registry and High Risk Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pancreas Cancer",
        "Pancreatitis",
        "Chronic Pancreatitis",
        "Pancreatic Cyst",
        "Family History of Pancreas Cancer",
        "Genetic Mutations"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1368,
      "start_date": "2013-03-01",
      "completion_date": "2033-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-11-19T03:21:18.900Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02775461"
    },
    {
      "nct_id": "NCT04955262",
      "title": "A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Bempegaldesleukin (NKTR-214)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "⁸⁹Zr-Df-IAB22M2C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-08",
      "completion_date": "2022-01",
      "has_results": false,
      "last_update_posted_date": "2021-07-08",
      "last_synced_at": "2026-11-19T03:21:18.900Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Portland, Oregon • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04955262"
    },
    {
      "nct_id": "NCT04123470",
      "title": "A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "delolimogene mupadenorepvec",
          "type": "GENETIC"
        },
        {
          "name": "atezolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "BIOLOGICAL"
      ],
      "sponsor": "Lokon Pharma AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2020-01-28",
      "completion_date": "2023-07-30",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-19T03:21:18.900Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04123470"
    },
    {
      "nct_id": "NCT04771520",
      "title": "Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Locally Advanced Malignant Solid Neoplasm",
        "Locally Advanced Melanoma",
        "Locally Advanced Primary Malignant Central Nervous System Neoplasm",
        "Locally Advanced Sarcoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Primary Malignant Central Nervous System Neoplasm",
        "Metastatic Sarcoma",
        "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Prognostic Stage IIIC Breast Cancer AJCC v8",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Stage IIIC Colorectal Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Avapritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-01-20",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-11-19T03:21:18.900Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04771520"
    }
  ]
}